Business context and reporting period
Prothena Corporation plc, an Ireland-based biotechnology company, filed its Form 10-K for the year ended December 31, 2015. The company had no approved commercial products and focused on antibody-based therapies targeting amyloidosis, Parkinson’s disease and inflammatory diseases.
- NEOD001: Phase 3 VITAL trial and planned Phase 2b PRONTO trial for AL amyloidosis.
- PRX002: Phase 1 development for Parkinson’s disease in collaboration with Roche.
- PRX003: Phase 1 development for inflammatory diseases, including psoriasis.
- ATTR program: Preclinical development for TTR amyloidosis.
The filing also presents unaudited fourth-quarter 2015 results. Prothena operated in one reportable segment and had 66 employees at December 31, 2015.
Financial performance and liquidity
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Total revenue | $1.6 million | $50.9 million | Down 97% |
| Research and development expense | $58.4 million | $38.5 million | Up 52% |
| General and administrative expense | $23.1 million | $19.1 million | Up 21% |
| Total operating expenses | $81.5 million | $57.5 million | Up 42% |
| Loss from operations | $(79.9) million | $(6.6) million | Higher loss |
| Net loss | $(80.6) million | $(7.2) million | Higher loss |
| Basic and diluted loss per share | $(2.66) | $(0.29) | Higher loss per share |
| Cash used in operating activities | $(62.5) million | $(0.7) million | Higher cash burn |
| Cash and cash equivalents | $370.6 million | $293.6 million | Up $77.0 million |
| Working capital | $355.2 million | $287.1 million | Up $68.1 million |
2015 revenue consisted primarily of Roche reimbursements: $5.1 million of development-cost reimbursement, of which $0.2 million was recognized as collaboration revenue, and $1.4 million of research-service reimbursement. Revenue declined sharply because 2014 included Roche’s $30.0 million upfront payment and $15.0 million clinical milestone payment.
Fourth-quarter 2015 revenue was $0.3 million, operating expenses were $24.5 million and net loss was $24.2 million, or $0.76 per share.
Financing activities provided $140.8 million in 2015, primarily from the April 2015 public offering, which generated approximately $131.5 million of net proceeds, plus proceeds from option exercises and related tax benefits. The company had no reported debt financing; total liabilities were $24.6 million, including $12.8 million of accrued research and development costs.
Material changes versus the prior comparable period
- Revenue fell by $49.2 million, principally because 2014 included substantial Roche upfront and milestone revenue that did not recur in 2015.
- R&D expense increased by $20.0 million, driven primarily by higher NEOD001 clinical-trial costs and additional spending on PRX003 and PRX002.
- G&A expense increased by $4.1 million due mainly to higher personnel, share-based compensation and legal costs.
- Operating cash use increased to $62.5 million from $0.7 million, reflecting the absence of 2014 Roche payments and substantially higher operating spending.
- Cash increased to $370.6 million despite the operating loss because of equity financing proceeds.
- Shares outstanding increased to 31.7 million at year-end from 27.4 million, reflecting the 2015 offering and option exercises.
- Share-based compensation expense increased to $10.4 million from $5.6 million.
Guidance, outlook, risks and unusual items
Management expected R&D and G&A expenses to increase in 2016. R&D growth was expected to be driven mainly by the VITAL Phase 3 trial, initiation of PRONTO and the ATTR preclinical program. Management also expected higher G&A costs to support the company’s expansion.
Management believed year-end cash and cash equivalents would fund obligations for at least the next twelve months, but stated that additional capital would likely be required to continue development and eventual commercialization. In January 2016, the company completed a further offering of 2,587,500 shares at $53.00 per share, generating approximately $128.6 million of net proceeds.
- NEOD001 clinical results remain subject to confirmation in controlled, later-stage trials; early Phase 1/2 biomarker results are not predictive of approval or commercial success.
- The company depends on third-party manufacturers, including Boehringer Ingelheim for clinical supplies, and has no internal manufacturing capacity.
- Roche controls most development and commercialization activities for PRX002 outside the United States and may terminate the agreement at will after applicable notice periods.
- For U.S. PRX002 development and commercialization, Prothena may be responsible for 30% of shared costs and would receive 30% of profits if it remains in the co-development arrangement.
- All product candidates remain subject to clinical, regulatory, manufacturing, reimbursement and competitive risks, and none had received marketing approval.
- Contractual obligations at year-end totaled $21.0 million, including $12.4 million of operating leases, $7.1 million of purchase commitments and $1.5 million under license agreements. Future Roche cost-sharing obligations were not determinable.
- The company reported no material pending legal proceedings, no off-balance-sheet arrangements and an unqualified audit opinion on both the financial statements and internal control over financial reporting.
Most important facts for investors to verify
- Whether VITAL and PRONTO produce statistically significant clinical benefits for NEOD001 and support regulatory filings.
- Updated cash-burn rates, remaining cash runway and the timing and terms of future capital raises.
- Roche’s continued funding, development progress and strategic commitment to PRX002.
- Clinical safety, enrollment, dosing and biomarker results for PRX002 and PRX003.
- Whether third-party manufacturing transfers and capacity are completed without supply interruptions or comparability issues.
- The potential dilution from future equity offerings, option exercises and outstanding equity awards.
- The effect of collaboration accounting, Roche reimbursements and milestone payments on reported revenue and R&D expense.